Results 111 to 120 of about 415,275 (258)

The Gut–Heart Axis in Systemic Sclerosis: Evidence From a Large Prospective Early Disease Cohort

open access: yesArthritis Care &Research, EarlyView.
Objective Cardiac involvement significantly impacts prognosis in systemic sclerosis (SSc), highlighting the need for early risk stratification. Gastrointestinal (GI) symptoms are common and often manifest early. Emerging data suggest a link between GI and cardiac manifestations, possibly through shared mechanisms like dysautonomia.
Francesca R. Di Ciommo   +9 more
wiley   +1 more source

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

open access: yesArthritis Care &Research, EarlyView.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci   +25 more
wiley   +1 more source

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

open access: yesArthritis Care &Research, EarlyView.
Objective Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS) syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures.
Kevin Byram   +25 more
wiley   +1 more source

Short‐term response to biologic therapy in psoriatic arthritis (PsA) is not influenced by disease duration at initiation of therapy

open access: yesArthritis Care &Research, Accepted Article.
Objectives We aimed to determine whether the short‐term response to biologics in biologic‐naïve psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods PsA patients who started biologic therapy from the year 2000 to 2025 were included for analysis. Patients considered in the early treatment (ET)
Sung Min Cho   +4 more
wiley   +1 more source

Is blood eosinophilia a treatable trait in chronic obstructive airway diseases? [PDF]

open access: yesFront Immunol
Massetti G   +4 more
europepmc   +1 more source

Caregiver Perspectives on the Burden of Disease and Treatment in Uncontrolled Gout

open access: yesArthritis Care &Research, EarlyView.
Objective Uncontrolled gout (UG) refers to persistently elevated serum urate (SU) levels >6 mg/dL and ongoing gout symptoms despite use of urate‐lowering therapy (ULT). The objective of this study was to evaluate the burden associated with informal caregiving for individuals with UG.
Angelo Gaffo   +6 more
wiley   +1 more source

The Development of Rheumatoid Arthritis‐Specific Ambulatory Care Sensitive Conditions: Results of a Consensus Process

open access: yesArthritis Care &Research, Accepted Article.
Objective Ambulatory care sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin   +7 more
wiley   +1 more source

A Meadow of Glomerular Cysts in Chronic Obstructive Nephropathy. [PDF]

open access: yesKidney Med
Taniguchi S   +7 more
europepmc   +1 more source

Beyond Visual Scoring: Computational CT‐analysis for HRCT based quantification of Interstitial Lung Disease in Inflammatory Rheumatic Disease

open access: yesArthritis Care &Research, Accepted Article.
Interstitial lung disease (IRD‐ILD) is a significant cause of morbidity and mortality in patients with inflammatory rheumatic disorders (IRD). High‐resolution computed tomography (HRCT) is widely considered the gold standard for the non‐invasive assessment of ILD; however, its interpretation is constrained by substantial inter‐observer variability and ...
Alexander Pfeil   +7 more
wiley   +1 more source

Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease. [PDF]

open access: yesFront Pharmacol
Wu JY   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy